Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

oughout the 6-month trial. Both groups had a significant improvement in glycemic control, with no increases in hypoglycemia (major hypoglycemic events were .02 event/patient/month for both groups) and minimal weight change (.2 kg for 303 Algorithm group and -.3 kg for Standard-of-Care group).

About Levemir(R)

Levemir(R) (insulin detemir [rDNA origin] injection) is a long-acting insulin analog indicated for once- or twice-daily subcutaneous administration for the treatment of adults and children with type 1 diabetes mellitus and adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. Levemir(R) has a relatively flat action profile with up to 24 hours duration of action. It can be added to oral anti-diabetic agents, or used in combination with a rapid-acting insulin. Levemir(R) is available in FlexPen(R), a prefilled disposable insulin pen for easy, discreet dosing and in vials.

Levemir(R) was approved by the U.S. Food and Drug Administration in June 2005 and was launched in the U.S. in March 2006. Levemir(R) has been available for use in Europe since March 2004 and is currently approved in 50 countries worldwide. Levemir(R) is contraindicated in patients hypersensitive to insulin detemir or its excipients. Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir(R). As with all insulins, the timing of hypoglycemic events may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes. Other adverse events commonly associated with insulin therapy may include injection site reactions (on average 3-4 percent of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment. Levemir(R) should not be dilut
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/3/2015)... (Nasdaq: DRRX ) announced today financial results for the ... net loss was $5.5 million for the three months ended ... million and net loss of $5.5 million for the three ... cash and investments of $37.8 million, compared to cash and ... 30, 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... 2015 Par Pharmaceutical Companies, Inc. announced today ... August 7, 2015 at 9:00 a.m. EDT to review ... June 30, 2015.  Par is privately held and currently ... its filings with the Securities and Exchange Commission and ... by following the instructions at http://www.parpharm.com/financialinfo .  Par ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4
... RAPIDS, Mich., May 31, 2011 The Neuroblastoma ... the opening of a first-of-its-kind genomic-based clinical trial ... relapsed and refractory neuroblastoma. The ... (VARI), is a nationwide network of pediatric cancer ...
... Life Technologies Corporation  (NASDAQ: LIFE ) today ... RNA-Seq Kit for the Ion Personal Genome Machine (PGM™) ... to microarrays for transcript expression analysis. The Ion PGM ... enabling scientists to get far more accurate and comprehensive ...
Cached Medicine Technology:Consortium Opens Landmark Personalized Medicine Children's Cancer Trial 2Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays 2Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays 3Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays 4
(Date:8/4/2015)... ... 2015 , ... Mr Didier Cauchois, CIO of information systems ... , Mr Cauchois attributes the success to the dedication from the team at ... technology offered by Winscribe's platform. , "We have already begun to see ...
(Date:8/3/2015)... ... August 04, 2015 , ... The ... a 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. She ... 700,000 members and over 200 operating Local Chapters, NAPW is the nation’s leading ...
(Date:8/3/2015)... ... August 04, 2015 , ... The American ... , The new internationally peer-reviewed Guidelines were prepared by members of the AAT ... imaging, in evaluating patients with dental-oral and systemic health-related complaints. , Thermography ...
(Date:8/3/2015)... , ... August 03, 2015 , ... sweetFrog Enterprises, LLC. ... location is the 20th sweetFrog store operating in the Lone Star State. The premium ... growing companies in 2014. , The store, located at 2916 US-75, Sherman, TX 38652, ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ( ... create efficiencies in healthcare information exchange, announced the release of its findings from its ... Services (HHS) Secretary, WEDI shared survey results and recommendations , strongly ...
Breaking Medicine News(10 mins):Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3Health News:sweetFrog Reopens Texas Store Today 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4
... of altruism; helping others ... one,s own health issues, CHICAGO, May 15 Meet Cindy Zamirowski, ... "cancer,free" thumbs up from her physician, stepped off the curb to raise ... The Bolingbrook mom of three and grandma of three rallied her ...
... to a new study from the University of Minnesota, the ... have been identified. The researchers found that the point of ... in receptor molecules, molecular "hooks" on the outer surface of ... of the bloodstream. The research appears in the May 15 ...
... ORLANDO, FL, May 20, 2008- Maxi-K gene therapy may ... whose erectile dysfunction (ED) is not treatable with oral ... Scientific Meeting of the American Urological Association (AUA) may ... to reporters in a special press conference on May ...
... FL, May 20, 2008 Transplantation of muscle-derived ... treatment for patients suffering from urinary incontinence following ... the 103rd Annual Scientific Meeting of the American ... resulting from iatrogenic sphincter damage may benefit from ...
... May 21, 2008Men aged 75-80 with prostate-specific antigen (PSA) ... discontinue their regular prostate cancer screenings, according to new ... the American Urological Association (AUA). Johns Hopkins University researchers ... a PSA level of 3 ng/ml or above had ...
... U.S. Hospitals, ANN ARBOR, Mich., May 14 ... 13 hospitals for excellence in,performance improvement at the ... the 2008 awards were announced during the Thomson,Reuters ... Resort,in Orlando, Florida., Temple University Health System ...
Cached Medicine News:Health News:After Effects: Giving Back Is Good for You 2Health News:U of Minnesota researcher discovers the starting point of sun-induced skin cancer 2Health News:AUA 2008: Maxi-K gene transfer may prove to be safe and effective erectile dysfunction treatment 2Health News:Regular prostate-specific antigen screening may be discontinued in certain elderly populations 2Health News:Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines 2
... semiconductor-based laser system representing the latest in technological ... for fast treatment of large areas (14 mm ... High power and large spot size optimize laser ... indicated for the treatment of vascular and pigmented ...
The Perkins has been established for well over 20 years as a "world standard" for hand held applanation tonometers....
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
Medicine Products: